No Data
Shengnuo Biotechnology (688117.SH): Lepu Medical Technology has cumulatively reduced its shareholding by 0.7912%.
On December 26, Gelonghui reported that Shengnuo Biology (688117.SH) announced that the company recently received a notification letter from Lepu Medical Technology regarding the results of shareholding reduction. As of the date of this announcement, Lepu Medical Technology has cumulatively reduced its shareholding by 889,445 shares through centralized bidding, accounting for 0.7912% of the company's total share capital. After the reduction, Lepu Medical Technology holds 5,272,000 shares of the company, accounting for 4.6896% of the company's total share capital, and this shareholding reduction plan has reached its expiration.
Lepu Medical Technology (300003.SZ): The transcatheter implanted aortic valve system has received registration approval.
Lepu Medical Technology (300003.SZ) announced that its subsidiary Lepu Xintai's product ScienCro ...
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotech-B (02157.HK) has signed a CDMO service framework agreement with lepu medical technology.
On November 26, Gleam Hill reported that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, pursuant to which the company and/or its subsidiaries agreed to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
HK stock market anomaly | Xintai Medical (02291) surged more than 30% in early trading. Recently renewed the framework agreement with lepu medical technology. The trade volume may increase year by year in the next three years.
Heartway Medical (02291) surged over 30% in the early session, as of the time of writing, it rose by 30.92%, reaching 22.1 Hong Kong dollars, with a transaction volume of 19.5613 million Hong Kong dollars.
Sinolink Securities: The advantage of "price + medical insurance" brings a breakthrough in CGM volume. Focus on the expansion of medical instruments in the European and American markets.
Europe and the United States occupy more than two-thirds of the global CGM market share, and the average selling price of CGM products is significantly higher compared to domestic prices. If domestic companies can expand overseas markets, they will unlock greater demand and higher price levels.
